Anti-cancer drug discovery: update and comparisons in yeast, Drosophila, and zebrafish
- PMID: 24993385
- PMCID: PMC4408876
- DOI: 10.2174/1874467207666140702113629
Anti-cancer drug discovery: update and comparisons in yeast, Drosophila, and zebrafish
Abstract
Discovery of novel cancer chemotherapeutics focuses on screening and identifying compounds that can target 'cancer-specific' biological processes while causing minimal toxicity to non-tumor cells. Alternatively, model organisms with highly conserved cancer-related cellular processes relative to human cells may offer new opportunities for anticancer drug discovery when combined with chemical screening. Some organisms used for chemotherapeutic discovery include yeast, Drosophila, and zebrafish which are similar in important ways relevant to cancer study but offer distinct advantages as well. Here, we describe these model attributes and the rationale for using them in cancer drug screening research.
Conflict of interest statement
The authors confirm that this article content has no conflict of interest.
References
-
- Sawyers C. Targeted cancer therapy. Nature. 2004;432:294–297. - PubMed
-
- Wiedemann LM, Morgan GJ. How Are Cancer Associated Genes Activated or Inactivated. Eur J Cancer. 1992;28A:248–251. - PubMed
-
- Spring DR. Chemical genetics to chemical genomics: small molecules offer big insights. Chem Soc Rev. 2005;34:472–482. - PubMed
-
- Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278:1064–1068. - PubMed
-
- Alcide Barberis TG, Catherine Berset, Stephan Audetat, Urs Lüthi. Yeast as a screening tool. Drug Discovery Today: Technologies. 2005;2:187–192. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
